0001415889-24-009334.txt : 20240328 0001415889-24-009334.hdr.sgml : 20240328 20240328163105 ACCESSION NUMBER: 0001415889-24-009334 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240326 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Johnston John Joseph CENTRAL INDEX KEY: 0001874850 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 24799619 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 form4-03282024_040349.xml X0508 4 2024-03-26 0001287098 MAXCYTE, INC. MXCT 0001874850 Johnston John Joseph C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 true false false false 1 Common Stock 2024-03-26 4 M 0 5000 2.142 A 125583 D Common Stock 2024-03-26 4 S 0 5000 4.405 D 120583 D Stock Option (right to buy) 2.142 2024-03-26 4 M 0 5000 0 D 2029-03-04 Common Stock 5000 617 D The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.37 to $4.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. /s/ Katie Kazem, Attorney-in-Fact 2024-03-28